Page 3 - Functional Class News Today

/PRNewswire/ -- Abbott (NYSE: ABT) today announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating...

Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 -- Liquidia Corporation announced today...

Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ labelLitigation is tied to same ‘793 patent...

MORRISVILLE, N.C., Aug. 10, 2023 -- Liquidia Corporation today reported financial results for the second quarter ended June 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss... -Today at 06:01 am- MarketScreener

No new clinical data is required to add PH-ILD indication as per FDA correspondenceRecertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for TyvasoPreparing for...

Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPRFederal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024If PTAB...

U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

Seralutinib treatment reduced pulmonary vascular resistance in heavily treated patients

Data presented at EuroPCR 2023 build on prior study results demonstrating TriClip is a safe and effective therapy to treat leaky tricuspid valves

Abbott today announced late-breaking data supporting the benefits of its TriClip transcatheter edge-to-edge repair (TEER) system.